Literature DB >> 17904553

Leishmania donovani: role of CD2 on CD4+ T-cell function in Visceral Leishmaniasis.

Sanjiva Bimal1, Shubhankar K Singh, Sukrat Sinha, Krishna Pandey, Prabhat K Sinha, Alok Ranjan, Sujit K Bhattacharya, Pradeep Das.   

Abstract

In this study, we investigated whether alteration in the CD2 mediated coordination of an immune response was associated with down regulation of CD4 associated Th1 cell response during Visceral Leishmaniasis (VL). Leishmania donovani (Ld) infection in VL patients markedly reduced expression of CD2 cell surface antigen on CD4+ cells. T-cells of VL patients were mostly in G0/G1 stage of the cell cycle (98.20%) with little or no activity of protein kinase C-alpha (PKC-alpha) isoform. However, pre-incubation with activating anti-CD2 monoclonal antibody (MAb) resulted in a corresponding increase up to 2.52-fold in T-cells of G2/M population supported by both activity and expression of PKC-alpha isoform. Furthermore, we observed that co-incubation of T-cell with anti-CD2 increased the lymphocyte-blast population in patients in whom the CD4 cells became more antigen responsive (CD4+ CD69+ cells). Consistent with these observations, it was shown that 59.3% of CD4 cells from patients responded to Ld by producing IFN-gamma. Even in the culture condition, when the T-cells from patients were depleted of APC, IFN-gamma production was noticed after CD2 activation. On the other hand, IL-4 production became low in the anti-CD2 antibody supplemented peripheral blood mononuclear cells (PBMNCs) culture. These findings imply that infection with L. donovani induces less CD2 on the surface of CD4+ T-cells, which once activated orchestrate the protective IFN-gamma dominant host defense mechanism via PKC-mediated signal transduction and cell cycle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904553     DOI: 10.1016/j.exppara.2007.08.009

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  5 in total

Review 1.  Deception and manipulation: the arms of leishmania, a successful parasite.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Nuno Santarém; Joana Maciel; Vasco Rodrigues; Anabela Cordeiro da Silva
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

Review 2.  Integrating Genomic and Morphological Approaches in Fish Pathology Research: The Case of Turbot (Scophthalmus maximus) Enteromyxosis.

Authors:  Paolo Ronza; Diego Robledo; Roberto Bermúdez; Ana Paula Losada; Belén G Pardo; Paulino Martínez; María Isabel Quiroga
Journal:  Front Genet       Date:  2019-01-31       Impact factor: 4.599

3.  Metagenomic Analysis Identifying a Rare Leishmania Infection in an Adult With AIDS.

Authors:  Pingping Song; Shuai Chen; Xiaoyu Tan; Yanjun Gao; Juanjuan Fu; Zhiqing You; Chengtan Wang; Qigang Zhao; Feng Pang
Journal:  Front Cell Infect Microbiol       Date:  2021-12-15       Impact factor: 5.293

4.  The role of mucosal-associated invariant T cells in visceral leishmaniasis.

Authors:  Marcela de Lima Moreira; Luana Oliveira Borges-Fernandes; Marcelo Antônio Pascoal-Xavier; Ágata Lopes Ribeiro; Victória Hellena Silva Pereira; Troi Pediongco; Márcio Sobreira da Silva Araújo; Andréa Teixeira-Carvalho; Andrea Lucchesi de Carvalho; Maria Vitória Assumpção Mourão; Flávia Alves Campos; Marineide Borges; Mariângela Carneiro; Zhenjun Chen; Eleanor Saunders; Malcolm McConville; Moriya Tsuji; James McCluskey; Olindo Assis Martins-Filho; Sidonia Barbara Guiomar Eckle; Jordana Grazziela Alves Coelho-Dos-Reis; Vanessa Peruhype-Magalhães
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

5.  Immunomodulation in human dendritic cells leads to induction of interferon-gamma production by Leishmania donovani derived KMP-11 antigen via activation of NF-κB in Indian kala-azar patients.

Authors:  Rajesh Chaudhary; Ajay Amit; Anupam Yadav; Anurag Singh; Vikash Kumar; S K Singh; Shyam Narayan; Vidyanand Rabidas; K Pandey; Anil Kumar; Pradeep Das; Sanjiva Bimal
Journal:  Biomed Res Int       Date:  2014-01-22       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.